China's 12th National Drug Volume-Based Procurement Sets Record with 77 Products; 7-Day Pre-Filing Window Opens
Johnson & Johnson
Medical Device R&D and Manufacturer
National Procurement No.12Batch officially begins，Filling Time:2026Year5Month15Day14:00—2026Year5Month21Day16:00(From today until next Thursday, within a week).
This Round of Centralized Procurement Pre-Reporting77Varieties included, totaling233Individual product specifications. This is the highest number in history (the last time was the tenth batch of 62 varieties compared over a long period). Previously, on March 20, the National Healthcare Security Administration released 151.Drugs with a potentially high number of enterprises passing the consistency evaluation but not yet included in the national centralized procurement.
Quick Overview of Key Points：
Time Node: May 15, 2026, 14:00 — May 21, 2026, 16:00 (Only 7 days, time is tight).
Reporting Object: By the end of 2025, varieties that meet the competitive landscape and reach the procurement scale (see the attached list for details).
Filling Entry: National Healthcare Security Administration Service Platform (fuwu.nhsa.gov.cn).
Key Impact: The data submitted this time will directly determine the selection range for subsequent hospital reporting, and underreporting will directly affect subsequent market access.
According to the requirements of the National Joint Procurement Office, this pre-filing is mainly aimed at the marketing authorization holders (MAH) of the following categories of drugs:
Reference Listed Drug: Reference preparations for generic drugs published by the National Medical Products Administration.
Generic Drug: Drugs that have passed or are deemed to have passed the consistency evaluation of quality and efficacy for generic drugs.
Transfer to China Pharmaceutical: Drugs that are transferred from overseas production to domestic production and meet the regulations.
1. If the same company has multiple varieties or specifications within the scope of this information submission, all must be reported.
2. The drug information filled in this time will serve as the selection range for subsequent medical institutions to report demand by brand.
3. The final scope of the new batch of centrally organized drug procurement by the state, as well as the qualification requirements for enterprise bidding, shall be subject to the procurement announcement to be released subsequently.
4. This pre-filing is an important part of the centralized bulk procurement of pharmaceuticals. All companies should pay high attention to it, timely fill in the information of eligible varieties, and avoid missing or incorrect reports that may affect subsequent participation in centralized bulk procurement and the listing on provincial platforms in China.
Key Focus Varieties:NovartisAce VarietySacubitril ValsartanSince its launch, it has been on a wild ride, with total sales across all terminals (hospitals, retail pharmacies, online pharmacies) exceeding 6 billion yuan in 2025. With the patent expiration in November 2026 and inclusion in China's national procurement program, it will face a sales cliff.
